Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer

Posted by |2020-02-12T17:18:39-08:00February 12th, 2020|

The RAS family of proteins are one of the hottest targets in cancer research despite being one of the hardest for drug hunters to hit. Revolution Medicines has raised $238 million in an IPO to finance development of therapies that it says can drug these molecules in a novel way. On Wednesday evening, Revolution priced […]

CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019

Posted by |2020-02-12T00:14:01-08:00February 12th, 2020|

CRISPR, capacity, and consolidation powered the cell and gene therapy space in 2019, but a proactive focus on patient access topped Falcon Therapeutics CEO Susan Nichols’ annual roundup. In what has become one of the most anticipated presentations at the Phacilitate Leaders World Conference, Susan Nichols, CEO of private North Carolina-based cell therapy firm Falcon […]

FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts

Posted by |2020-02-10T15:51:26-08:00February 10th, 2020|

The FDA has placed a clinical hold on a LogicBio Therapeutics application to begin human testing of its experimental gene-editing therapy for a rare, inherited liver disorder. LogicBio (NASDAQ: LOGC) disclosed the clinical hold for its gene-editing therapy, LB-001, after Monday’s market close. The Cambridge, MA-based biotech said that the hold concerns “certain clinical and […]

Takeda’s Peng Lu Joins Pharvaris as Chief Medical Officer

Posted by |2020-02-10T02:30:19-08:00February 7th, 2020|

Pharvaris has appointed Peng Lu to serve in the newly created position of chief medical officer. Lu joins the Leiden, Netherlands-based drug developer from Takeda Pharmaceutical (NYSE: TAK), where she was vice president and global program lead for rare diseases. Lu will be based in Pharvaris’s Boston office. The company’s lead drug candidate, PHA121, is […]

Myriad Genetics Exec Capone Resigns, Riggsbee Named Interim CEO

Posted by |2020-02-06T16:57:26-08:00February 6th, 2020|

Longtime Myriad Genetics (NASDAQ: MYGN) president and CEO Mark Capone has resigned. The Salt Lake City-based molecular diagnostic company said Myriad and Capone—who has been with the company for 17 years—mutually agreed it was the right time for a leadership transition. Bryan Riggsbee, Myriad’s chief financial officer, was appointed interim president and CEO. He will […]

Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered

Posted by |2020-02-06T02:28:32-08:00February 6th, 2020|

Gene editing biotech Beam Therapeutics raised $180 million in its initial public offering Wednesday after offering 48 percent more shares than it initially anticipated. Beam, which was slated to begin trading Thursday on the Nasdaq exchange under the stock symbol “BEAM,” sold 9.25 million shares, up from the 6.25 million it said it planned to […]

Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA

Posted by |2020-02-04T16:32:03-08:00February 4th, 2020|

Titan Medical didn’t meet its goal of submitting its robotic surgical system for FDA clearance by the end of 2019. Now the company says it needs another $85 million to get its medical device to the finish line or it might have to put itself up for sale. The robotic systems developer spelled out the […]

Passage Bio Plans IPO as Three Gene Therapies Approach the Clinic

Posted by |2020-02-03T20:12:42-08:00February 3rd, 2020|

A year ago Passage Bio launched with $115.5 million and plans to advance a handful of gene therapies discovered at the University of Pennsylvania. Now the Philadelphia-based biotech is preparing to join the public markets and raise millions more to move its three lead programs into the clinic. Passage, which has three preclinical programs and […]
Go to Top